Risk Based Assessment of Elemental Impurities According to ICH Q3D Guideline: Application to an Oral Solid Dosage Form

Background: Elemental impurities (EIs) in pharmaceutical products may originate from active pharmaceutical ingredients, excipients, manufacturing equipment, utilities, and packaging materials. The ICH Q3D guideline provides a risk-based framework for evaluating and controlling these impurities according to their permitted daily exposure (PDE). This study aimed to perform a comprehensive assessment of elemental impurity risks in an oral solid dosage form using the ICH Q3D component approach (Option 2b), complemented by a quality risk assessment of manufacturing equipment. Methods: The elemental impurity risk assessment was performed using the component approach (Option 2b), considering the active pharmaceutical ingredient (API), four pharmaceutical excipients, manufacturing equipment, primary packaging, and purified water. Supplier data and available analytical results were used to estimate the daily contribution of Class 1 elements (Cd, Pb, As, and Hg) and Class 2A elements (Co, V, and Ni). The calculated patient exposure was compared with the corresponding oral PDE values established by ICH Q3D. Manufacturing equipment was additionally evaluated using Failure Mode and Effects Analysis (FMEA) to identify potential failure modes and assess the effectiveness of existing control measures. Results: The API showed consistently low concentrations of the investigated elemental impurities, with values ≤0.1 µg/g across three independent batches. The assessment of the four excipients indicated no intentional addition of the investigated elemental impurities and low overall contributions to patient exposure. Manufacturing equipment presented a negligible residual risk following the implementation of GMP controls, including equipment qualification, cleaning procedures, preventive maintenance, and visual inspection. The estimated total daily exposures were 0.27, 0.27, 0.27, 0.28, 0.29, 0.32, and 1.66 µg/day for Cd, Pb, As, Hg, Co, V, and Ni, respectively. These values corresponded to 5.4%, 5.4%, 1.8%, 0.9%, 0.58%, 0.32%, and 0.83% of their respective PDEs, all remaining well below the 30% PDE threshold used for the control strategy. Primary packaging and purified water were also considered negligible contributors. Conclusion: The ICH Q3D component approach (Option 2b), combined with systematic quality risk management of manufacturing equipment, provided a practical and scientifically justified framework for elemental impurity assessment in the investigated oral solid dosage form. The estimated exposures were substantially below the applicable PDE values, supporting the adequacy of the existing control measures and indicating that no additional elemental impurity-specific controls were required. This approach may support efficient risk-based decision-making and routine pharmaceutical quality management when reliable supplier and process data are available.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1842.v1
Primary Topic
Analytical Methods in Pharmaceuticals
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Risk Based Assessment of Elemental Impurities According to ICH Q3D Guideline: Application to an Oral Solid Dosage Form

Lamyae Yachi, Khalid Karrouchi, BOUATIA Mustapha, Brahim Mojemmi
Preprints.org
Analytical Methods in Pharmaceuticals
preprint

Risk Based Assessment of Elemental Impurities According to ICH Q3D Guideline: Application to an Oral Solid Dosage Form

Lamyae Yachi, Khalid Karrouchi, BOUATIA Mustapha, Brahim Mojemmi
preprint en

Abstract

Background: Elemental impurities (EIs) in pharmaceutical products may originate from active pharmaceutical ingredients, excipients, manufacturing equipment, utilities, and packaging materials. The ICH Q3D guideline provides a risk-based framework for evaluating and controlling these impurities according to their permitted daily exposure (PDE). This study aimed to perform a comprehensive assessment of elemental impurity risks in an oral solid dosage form using the ICH Q3D component approach (Option 2b), complemented by a quality risk assessment of manufacturing equipment. Methods: The elemental impurity risk assessment was performed using the component approach (Option 2b), considering the active pharmaceutical ingredient (API), four pharmaceutical excipients, manufacturing equipment, primary packaging, and purified water. Supplier data and available analytical results were used to estimate the daily contribution of Class 1 elements (Cd, Pb, As, and Hg) and Class 2A elements (Co, V, and Ni). The calculated patient exposure was compared with the corresponding oral PDE values established by ICH Q3D. Manufacturing equipment was additionally evaluated using Failure Mode and Effects Analysis (FMEA) to identify potential failure modes and assess the effectiveness of existing control measures. Results: The API showed consistently low concentrations of the investigated elemental impurities, with values ≤0.1 µg/g across three independent batches. The assessment of the four excipients indicated no intentional addition of the investigated elemental impurities and low overall contributions to patient exposure. Manufacturing equipment presented a negligible residual risk following the implementation of GMP controls, including equipment qualification, cleaning procedures, preventive maintenance, and visual inspection. The estimated total daily exposures were 0.27, 0.27, 0.27, 0.28, 0.29, 0.32, and 1.66 µg/day for Cd, Pb, As, Hg, Co, V, and Ni, respectively. These values corresponded to 5.4%, 5.4%, 1.8%, 0.9%, 0.58%, 0.32%, and 0.83% of their respective PDEs, all remaining well below the 30% PDE threshold used for the control strategy. Primary packaging and purified water were also considered negligible contributors. Conclusion: The ICH Q3D component approach (Option 2b), combined with systematic quality risk management of manufacturing equipment, provided a practical and scientifically justified framework for elemental impurity assessment in the investigated oral solid dosage form. The estimated exposures were substantially below the applicable PDE values, supporting the adequacy of the existing control measures and indicating that no additional elemental impurity-specific controls were required. This approach may support efficient risk-based decision-making and routine pharmaceutical quality management when reliable supplier and process data are available.

Preprints.org
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon